Skip to main content
Livermore
Livermore
ZHEN

HighTower Advisors, LLC

SEC CIK
0001462245
Latest filing
Aug 25, 2026

HALO holding history

Halozyme Therapeutics, Inc. in every 13F filed by HighTower Advisors, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HALO overviewAll 13F holders of HALOFull Q2 2026 holdings

Shares (Q2 2026)
15,024
Value
$1.18M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of HALO by HighTower Advisors, LLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202615,024$1.18M<0.1%−2,817−15.8%ReducedHolders
Q1 202617,841$1.15M<0.1%−4,548−20.3%ReducedHolders
Q4 202522,389$1.51M<0.1%−3,749−14.3%ReducedHolders
Q3 202526,138$1.92M<0.1%+8,007+44.2%AddedHolders
Q2 202518,131$943.2K<0.1%−6,263−25.7%ReducedHolders
Q1 202524,394$1.56M<0.1%+7,800+47.0%AddedHolders
Q4 202416,594$793.4K<0.1%−19,580−54.1%ReducedHolders
Q3 202436,174$2.08M<0.1%+6,075+20.2%AddedHolders
Q2 202430,099$1.58M<0.1%+5,000+19.9%AddedHolders
Q1 202425,099$1.01M<0.1%−8,522−25.3%ReducedHolders
Q4 202333,621$1.24M<0.1%+14,633+77.1%AddedHolders
Q3 202318,988$725.0K<0.1%+583+3.2%AddedHolders
Q2 202318,405$668.0K<0.1%+563+3.2%AddedHolders
Q1 202317,842$680.0K<0.1%−72,510−80.3%ReducedHolders
Q4 202290,352$5.14M<0.1%−5,953−6.2%ReducedHolders
Q3 202296,305$3.82M<0.1%+80,941+526.8%AddedHolders
Q2 202215,364$674.0K<0.1%+3,412+28.5%AddedHolders
Q1 202211,952$477.0K<0.1%+812+7.3%AddedHolders
Q4 202111,140$446.0K<0.1%+1,505+15.6%AddedHolders
Q3 20219,635$391.0K<0.1%−519−5.1%ReducedHolders
Q2 202110,154$461.0K<0.1%+896+9.7%AddedHolders
Q1 20219,258$387.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.